. Author manuscript; available in PMC: 2014 Mar 1.

Published in final edited form as: Pharmacotherapy. 2013 Feb 11;33(3):e19–e22. doi: 10.1002/phar.1192

Table 1.

Intravenous Voriconazole Pharmacokinetic Parameters in Three Obese Patients.

Pharmacokinetic Parameter	Case 1 (This Case)	Case 2⁷	Case 3⁵
Age (years)	17	41	30
BMI (kg/m²)	35	36	84.5
TBW (kg)	102.1	134.5	225
ABW (kg)	85^a	101.3^b	Not reported^a
CYP2C19 genotype	CYP2C192/2	CYP2C192/2	Not reported
IV voriconazole dosage	4 mg/kg	4 mg/kg	4 mg/kg
IV voriconazole dose (based upon ABW) every 12 hours	340 mg^c	405 mg^d	Not reported^e
AUC_0–12(ng•h/ml)	86,100	77,790	41,850
Clearance (L/h)	3.9	5.01	Not reported
Vd (L)	157	221	Not reported
t_1/2(h)^f	29.3	30	Not reported
trough (mcg/ml)	6.2	6.1	Not reported

BMI = body mass index; TBW = total body weight; ABW = adjusted body weight; AUC_0–12 = area under the serum concentration versus time curve over the course of a single dosing interval; Vd = volume of distribution; t_1/2 = half-life.

ABW = IBW + 0.4 (TBW – IBW)

ABW = IBW + 0.3 (TBW – IBW)

infusion time (1.75 h), collection time points from beginning of infusion (2.75, 5.75, 9.75, 11.75 h).

infusion time (1.75 h); collection time points from beginning of infusion (2.5, 5.6, 9.5, 11.5 h).

infusion time not reported; collection time points from beginning of infusion (1, 5, 9, 12 h).

The elimination rate constant (λ_z) was estimated as the absolute value of the slope of a linear regression of a natural logarithm of concentration versus time using at least 3 points on the line. Half-life (t_1/2) was calculated as ln2/λ_z.